Tryptamine Therapeutics
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
697 Burke Rd Ste 201, Camberwell, Victor...Phone Number
+61 390920475Website
www.tryptherapeutics.comRevenue
-Stock Symbol
TYPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Tryptamine Therapeutics
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.Explore more
Tryptamine Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tryptamine Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Tryptamine Therapeutics recently announced quarterly report
Tryptamine Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Tryptamine Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tryptamine Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Tryptamine Therapeutics
Check out if Tryptamine Therapeutics is spiking on competitors!
Click to see if Tryptamine Therapeutics had a recent Job posting/layoffs
Check if Tryptamine Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Tryptamine Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Tryptamine Therapeutics
Compare insights from companies similar to Tryptamine Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tryptamine Therapeutics
1-10
Public
$12.4M
2019
Hamish GeorgeChief Financial Officer & Company Secretary
Company Profile Activity
Activity Insights
Tryptamine Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tryptamine Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tryptamine Therapeutics.
Tryptamine Therapeutics financials insights
Gather financial insights about Tryptamine Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$4.3M
2022
Share Placement
$2M
2025
Stock/Share Issuance
$6.1M
Tryptamine Therapeutics Tech Stack
A closer look at the technologies used by Tryptamine Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Lateral Move
Executive Move
Tryptamine Therapeutics News & Media
Tryptamine Therapeutics raises A$6M to advance psychedelic pipeline
The placement is a bright spot in an otherwise quiet period for psychedelics industry financing, as investors grow selective.Tryptamine Therapeutics Welcomes New CFO - TipRanks.com
Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited has announced the appointment of Hamish George as the new Chief Financial O...Tryptamine Therapeutics Limited Announces Chief Financial Officer Changes
Tryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer , effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has...Tryp Therapeutics merger with Exopharm approved by shareholders - Green Market Report
The move is expected to provide the company with more visibility and access to a broader investor base in order to advance its pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Tryptamine Therapeutics
Sign Up For FreeTo access detailed company insights
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formula... Read More
